Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar Drug), US Licenced Avastin and EU Approved Avastin in Healthy Male Volunteers

Next Previous
Search
Trial Profile

A Randomised, Double Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar Drug), US Licenced Avastin and EU Approved Avastin in Healthy Male Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma
  • Focus Pharmacokinetics
  • Sponsors mAbxience

    • Most Recent Events

    • 09 Aug 2021 Result (n=114) assessing pharmacokinetic equivalence in healthy male volunteers between MB02 and the reference bevacizumab, as well as comparable safety and immunogenicity profile, published in the British Journal of Clinical Pharmacology.
    • 07 Sep 2020 Status changed from active, no longer recruiting to completed.
    • 27 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top